alendronate has been researched along with Fracture, Pathologic in 107 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The objective of this study was to address the possibility that treatment with alendronate and vitamin D2 may reduce the incidence of hip fractures in elderly women with PD." | 5.12 | Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: a randomized controlled trial. ( Iwamoto, J; Kanoko, T; Sato, Y; Satoh, K, 2006) |
| " The fractures were associated with 6 years of oral alendronate treatment immediately followed by subcutaneous denosumab therapy and later teriparatide therapy for osteoporosis." | 5.01 | Antiresorptive-associated spontaneous fractures of both tibiae, followed by an atypical femur fracture during the sequential treatment with alendronate, denosumab then teriparatide. ( Poole, K; Sano, H; Tan, J, 2019) |
| "Alendronate and risedronate have been the standard regimens in the pharmacological intervention of osteoporosis based on their accumulated evidences of fracture prevention." | 4.85 | [New development in bisphosphonate treatment. Fracture prevention by bisphosphonates]. ( Hosoi, T, 2009) |
| " In Japan, at present, only weekly alendronate and risedronate, both oral, have been approved for osteoporosis." | 4.85 | [New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates]. ( Okazaki, R, 2009) |
| " We performed additional analyses of phase III clinical trial and compared the effect of minodronic acid hydrate on bone turnover markers with those of alendronate in primary osteoporosis." | 4.85 | [New development in bisphosphonate treatment. Review of effect on bone metabolism by minodronic acid in primary osteoporosis]. ( Fukunaga, M, 2009) |
| "We studied 26,636 new users of an osteoporosis medication (alendronate, calcitonin, estrogen, raloxifene, or risedronate) who were age 65 or older and had an extended lapse in refill compliance, defined as a period of at least 60 days after the completion of one prescription in which no refill for any osteoporosis medication was obtained." | 3.74 | Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. ( Arnold, M; Avorn, J; Brookhart, MA; Finkelstein, JS; Katz, JN; Mogun, H; Patrick, AR; Polinski, JM; Solmon, DH, 2007) |
| "Alendronate treatment is estimated to result in increases in hip bone density >or=0." | 2.74 | Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data. ( Bauer, DC; Bell, KJ; Craig, JC; Ensrud, K; Hayen, A; Irwig, L; Macaskill, P, 2009) |
| "Gorham's disease is progressive in most patients; yet it can be self-limiting in a few reported cases." | 2.53 | Novel approach of treating Gorham-Stout disease in the humerus--Case report and review of literature. ( Al-Hussaini, M; Attili, A; Ellati, R; Haddad, H; Shehadeh, A, 2016) |
| " Also reviewed are results of "bridging" studies designed to demonstrate the comparable efficacy of less frequent dosing regimens to increase bone mineral density and to reduce bone turnover." | 2.45 | Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. ( Bilezikian, JP, 2009) |
| " The potent bisphosphonate zoledronate can be given at intervals of as long as 1 year and produces changes in bone density and in markers of bone turnover comparable with those seen with conventional daily oral dosing with alendronate or risedronate." | 2.42 | Bisphosphonates: new indications and methods of administration. ( Reid, IR, 2003) |
| "Food and Drug Administration for the treatment of postmenopausal osteoporosis include the bisphosphonates risedronate and alendronate; the selective estrogen receptor modulator, raloxifene; and intranasal calcitonin-salmon spray." | 2.42 | An approach to postmenopausal osteoporosis treatment: a case study review. ( Kessenich, C, 2003) |
| " Alternative dosing schedules and routes of administration have become available and may improve fracture protection, compliance, and tolerability for the long term treatment of a chronic condition such as osteoporosis." | 2.42 | Oral antiresorptive therapy. ( Hosking, DJ; Pande, I, 2004) |
| "Osteoporosis is a common complication of Cushing's disease/syndrome." | 2.41 | Osteoporotic fractures at presentation of Cushing's disease: two case reports and a literature review. ( Crouzet, J; Fournier, JJ; Khanine, V; Luton, JP; Requeda, E; Simon, F, 2000) |
| "She had been treated for postmenopausal osteoporosis with 70 mg of alendronate weekly for 2 years." | 1.91 | A Case Report of Oral Bisphosphonate Treatment for Osteoporosis Leading to Atypical Femoral Fracture and Pathologic Mandibular Fracture. ( Fernandes, TL; Franco, GCN; Jitumori, C; Viezzer Fernandes, B, 2023) |
| "There are very few cases of pathological fracture induced by pancreatitis that affect the vertebrae." | 1.37 | Pathological fracture due to vertebral osteonecrosis associated with pancreatitis. ( Baba, T; Kaneko, H; Shitoto, K; Yoshioka, C, 2011) |
| "Gorham-Stout disease, or massive osteolysis, is an extremely rare idiopathic condition characterized by spontaneous, localized relentless resorption of one or several contiguous bones." | 1.36 | Conservative treatment of a pathologic fracture in a patient with Gorham-Stout disease. ( McCain, JP; Pedroletti, F; Rangarajan, S; Velez, I, 2010) |
| "Histopathologic analysis revealed a parathyroid adenoma." | 1.36 | Primary hyperparathyroidism with classic and severe skeletal involvement. ( Paz-Pacheco, E; Sandoval, MA, 2010) |
| " Strategies to improve adherence to osteoporosis therapy include reducing dosing frequency, changing the route of administration, educating the patient about optimum bisphosphonate administration, and sending patient reminders." | 1.35 | Maximizing effectiveness of bisphosphonate therapy for osteoporosis. ( Martens, MG; Shaw, H, 2008) |
| "A total of 196 consecutive patients treated for distal radius fractures were included in this study." | 1.35 | Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy. ( Ayogu, N; Bouxsein, ML; Chacko, AT; Rozental, TD; Vazquez, MA, 2009) |
| " The hypothesis of a negative pharmacodynamic interaction between bisphosphonates, PPIs and corticosteroids which could lead to a decrease in bone strength after long-term use needs further investigation." | 1.35 | Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. ( Dayer, P; Desmeules, J; Ing-Lorenzini, K; Peter, R; Plachta, O; Suva, D, 2009) |
| "Treatment with alendronate (Fosamax) reduces the risk of osteoporotic fractures at the spine, hip and wrist in women with and without prevalent vertebral fracture." | 1.34 | Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries--an economic evaluation based on the fracture intervention trial. ( Boonen, S; Borgström, F; Haentjens, P; Johnell, O; Kanis, JA; Sen, SS; Ström, O, 2007) |
| "Alendronate has been studied extensively by large trials of high quality and its efficacy to reduce the risk of vertebral and nonvertebral fractures is in line with the criteria of evidence-based medicine." | 1.33 | [Drug therapy for prevention of falls and fractures]. ( Ringe, JD, 2006) |
| "Alendronate was significantly more effective than risedronate, calcitonin, estrogen, etidronate, and raloxifene (Relative Risks: 0." | 1.32 | Putting evidence-based medicine into clinical practice: comparing anti-resorptive agents for the treatment of osteoporosis. ( Hochberg, MC; Hosking, D; Wehren, LE, 2004) |
| "Because on bone marker measurement bone resorption was increased and bone formation was decreased from baseline, treatment was switched to oral alendronate (5 mg/day, daily)." | 1.31 | Insufficiency fracture of the femoral neck during osteoporosis treatment: a case report. ( Iwamoto, J; Takeda, T, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (8.41) | 18.2507 |
| 2000's | 75 (70.09) | 29.6817 |
| 2010's | 22 (20.56) | 24.3611 |
| 2020's | 1 (0.93) | 2.80 |
| Authors | Studies |
|---|---|
| Fernandes, TL | 1 |
| Viezzer Fernandes, B | 1 |
| Jitumori, C | 1 |
| Franco, GCN | 1 |
| Mathonet, PY | 1 |
| Willems, S | 1 |
| Ciornohac, JF | 1 |
| Tan, J | 1 |
| Sano, H | 1 |
| Poole, K | 1 |
| Skoglund, K | 1 |
| Hjortdal, O | 1 |
| Ellati, R | 1 |
| Attili, A | 1 |
| Haddad, H | 1 |
| Al-Hussaini, M | 1 |
| Shehadeh, A | 1 |
| Paccou, J | 1 |
| Sánchez, A | 1 |
| Blanco, R | 1 |
| Martens, MG | 1 |
| Shaw, H | 1 |
| Ofluoglu, O | 1 |
| Ofluoglu, D | 1 |
| Holder, KK | 1 |
| Kerley, SS | 1 |
| Hosoi, T | 1 |
| Okazaki, R | 1 |
| Yamaguchi, T | 1 |
| Sugimoto, T | 1 |
| Fukunaga, M | 1 |
| Bilezikian, JP | 1 |
| Eiken, PA | 2 |
| Abrahamsen, B | 1 |
| Rozental, TD | 1 |
| Vazquez, MA | 1 |
| Chacko, AT | 1 |
| Ayogu, N | 1 |
| Bouxsein, ML | 1 |
| Harada, A | 2 |
| Kuroda, T | 1 |
| Miyakawa, N | 1 |
| Miyazaki, T | 1 |
| Shiraki, M | 2 |
| Wongchuensoontorn, C | 1 |
| Liebehenschel, N | 1 |
| Wagner, K | 1 |
| Fakler, O | 1 |
| Gutwald, R | 1 |
| Schmelzeisen, R | 1 |
| Sauerbier, S | 1 |
| Bell, KJ | 1 |
| Hayen, A | 1 |
| Macaskill, P | 1 |
| Irwig, L | 1 |
| Craig, JC | 1 |
| Ensrud, K | 2 |
| Bauer, DC | 1 |
| Ali, T | 1 |
| Jay, RH | 1 |
| Asano, S | 1 |
| Suzuki, A | 1 |
| Itoh, M | 1 |
| Ing-Lorenzini, K | 1 |
| Desmeules, J | 1 |
| Plachta, O | 1 |
| Suva, D | 1 |
| Dayer, P | 1 |
| Peter, R | 1 |
| Pedroletti, F | 1 |
| Rangarajan, S | 1 |
| McCain, JP | 1 |
| Velez, I | 1 |
| Gorai, I | 1 |
| Hori, H | 1 |
| Baba, T | 1 |
| Shitoto, K | 1 |
| Yoshioka, C | 1 |
| Kaneko, H | 1 |
| Kuijpers, SC | 1 |
| van Roessel, EW | 1 |
| van Merkesteyn, JP | 1 |
| Scoletta, M | 1 |
| Arduino, PG | 1 |
| Dalmasso, P | 1 |
| Broccoletti, R | 1 |
| Mozzati, M | 1 |
| Gallego, L | 1 |
| Junquera, L | 1 |
| Pelaz, A | 1 |
| Costilla, S | 1 |
| Ott, SM | 1 |
| Soen, S | 1 |
| Wang, K | 1 |
| Moaveni, A | 1 |
| Dowrick, A | 1 |
| Liew, S | 1 |
| Unnanuntana, A | 2 |
| Ashfaq, K | 1 |
| Ton, QV | 1 |
| Kleimeyer, JP | 1 |
| Lane, JM | 3 |
| Rebolledo, BJ | 1 |
| Rasmussen, M | 1 |
| Lange, J | 1 |
| González López-Valcárcel, B | 1 |
| Sosa Henríquez, M | 1 |
| Ghazali, N | 1 |
| Collyer, JC | 1 |
| Tighe, JV | 1 |
| Sandoval, MA | 1 |
| Paz-Pacheco, E | 1 |
| Robinson, PJ | 1 |
| Bell, RJ | 1 |
| Lanzafame, A | 1 |
| Segal, L | 1 |
| Kirby, C | 1 |
| Piterman, L | 1 |
| Davis, SR | 1 |
| McCarthy, EA | 1 |
| Raggio, CL | 1 |
| Hossack, MD | 1 |
| Miller, EA | 1 |
| Jain, S | 1 |
| Boskey, AL | 1 |
| Camacho, NP | 1 |
| Heijckmann, AC | 1 |
| Juttmann, JR | 1 |
| Wolffenbuttel, BH | 1 |
| Iwamoto, J | 2 |
| Takeda, T | 1 |
| Reid, IR | 1 |
| Nakamura, T | 1 |
| Brixen, KT | 1 |
| Mosekilde, L | 2 |
| Jönsson, L | 1 |
| Borgström, F | 2 |
| Zethraeus, N | 1 |
| Kessenich, C | 1 |
| Lamy, O | 1 |
| Krieg, MA | 1 |
| Curković, B | 1 |
| Wehren, LE | 2 |
| Hosking, D | 1 |
| Hochberg, MC | 2 |
| Mazanec, D | 1 |
| Siris, ES | 1 |
| Chen, YT | 1 |
| Abbott, TA | 1 |
| Barrett-Connor, E | 2 |
| Miller, PD | 1 |
| Berger, ML | 1 |
| Adachi, JD | 1 |
| Woo, A | 1 |
| Hittell, J | 1 |
| Beardsley, C | 1 |
| Noh, C | 1 |
| Stoukides, CA | 1 |
| Kaul, AF | 1 |
| Bartl, R | 1 |
| Ringe, JD | 2 |
| Orimo, H | 1 |
| Delmas, PD | 1 |
| McClung, M | 1 |
| Pande, I | 1 |
| Hosking, DJ | 1 |
| Christoffersen, H | 1 |
| Holmegaard, SN | 1 |
| Sato, Y | 1 |
| Kanoko, T | 1 |
| Satoh, K | 1 |
| Kabi, F | 1 |
| Mkinsi, O | 1 |
| Zrigui, J | 1 |
| Wong, P | 1 |
| Anpalahan, M | 1 |
| Yamamoto, S | 1 |
| Kurato, S | 1 |
| Iwase, T | 1 |
| Inoue, K | 1 |
| Sasaki, Y | 1 |
| Tanaka, T | 1 |
| Fujita, M | 1 |
| Nakano, T | 1 |
| Ando, F | 1 |
| Vestergaard, P | 1 |
| Langdahl, B | 1 |
| Talbi, M | 1 |
| Carrie, F | 1 |
| Meley, M | 1 |
| Briot, K | 1 |
| Trémollières, F | 1 |
| Thomas, T | 1 |
| Roux, C | 1 |
| Ström, O | 1 |
| Sen, SS | 1 |
| Boonen, S | 1 |
| Haentjens, P | 1 |
| Johnell, O | 2 |
| Kanis, JA | 1 |
| Brookhart, MA | 1 |
| Avorn, J | 1 |
| Katz, JN | 1 |
| Finkelstein, JS | 1 |
| Arnold, M | 1 |
| Polinski, JM | 1 |
| Patrick, AR | 1 |
| Mogun, H | 1 |
| Solmon, DH | 1 |
| Gold, DT | 1 |
| Martin, BC | 1 |
| Frytak, JR | 1 |
| Amonkar, MM | 1 |
| Cosman, F | 1 |
| Epstein, S | 1 |
| Papierska, L | 1 |
| Rabijewski, M | 1 |
| Wells, GA | 1 |
| Cranney, A | 1 |
| Peterson, J | 1 |
| Boucher, M | 1 |
| Shea, B | 1 |
| Robinson, V | 1 |
| Coyle, D | 1 |
| Tugwell, P | 1 |
| Häuselmann, HJ | 1 |
| Cummings, SR | 3 |
| Kopjar, B | 1 |
| Bjørndal, A | 1 |
| Downs, RW | 1 |
| Bone, HG | 1 |
| McIlwain, H | 1 |
| Baker, MZ | 1 |
| Yates, AJ | 1 |
| Lombardi, A | 1 |
| Krupa, D | 1 |
| Harning, R | 1 |
| Ross, PD | 1 |
| Black, D | 1 |
| Genant, HK | 2 |
| Nevitt, MC | 1 |
| Musliner, T | 1 |
| Thompson, D | 1 |
| Høiseth, A | 1 |
| el Maghraoui, A | 1 |
| Lecoules, S | 1 |
| Lechevalier, D | 1 |
| Magnin, J | 1 |
| Eulry, F | 1 |
| Klovning, A | 1 |
| Norheim, OF | 1 |
| Khanine, V | 1 |
| Fournier, JJ | 1 |
| Requeda, E | 1 |
| Luton, JP | 1 |
| Simon, F | 1 |
| Crouzet, J | 1 |
| Kaufman, JM | 1 |
| Abadie, E | 1 |
| Adami, S | 2 |
| Audran, M | 1 |
| Avouac, B | 1 |
| Sedrine, WB | 1 |
| Calvo, G | 1 |
| Devogelaer, JP | 1 |
| Fuchs, V | 1 |
| Kreutz, G | 1 |
| Nilsson, P | 1 |
| Pols, H | 1 |
| Ringe, J | 1 |
| Van Haelst, L | 1 |
| Reginster, JY | 1 |
| Khan, SN | 1 |
| O'Connor, WJ | 1 |
| Nydick, M | 1 |
| Hommen, JP | 1 |
| Schneider, R | 1 |
| Tomin, E | 1 |
| Brand, J | 1 |
| Curtin, J | 1 |
| Harsch, IA | 1 |
| Hübner, RH | 1 |
| Hahn, EG | 1 |
| Hensen, J | 1 |
| Prizzi, R | 1 |
| Colapietro, F | 1 |
| Kruse, HP | 1 |
| Karpf, DB | 1 |
| Harris, F | 1 |
| LaCroix, AZ | 1 |
| Black, DM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 5-year, Double-blind, Randomized, Placebo-controlled Extension Study to Examine the Long-term Safety and Efficacy of Oral Alendronate in Postmenopausal Women Who Previously Received Alendronate in Conjunction With the Fracture Intervention Trial[NCT00398931] | Phase 3 | 1,099 participants (Actual) | Interventional | 1998-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
29 reviews available for alendronate and Fracture, Pathologic
| Article | Year |
|---|---|
Antiresorptive-associated spontaneous fractures of both tibiae, followed by an atypical femur fracture during the sequential treatment with alendronate, denosumab then teriparatide.
Topics: Absorptiometry, Photon; Adult; Alendronate; Bone Density; Denosumab; Dose-Response Relationship, Dru | 2019 |
Novel approach of treating Gorham-Stout disease in the humerus--Case report and review of literature.
Topics: Adolescent; Alendronate; Bone Density Conservation Agents; Combined Modality Therapy; Fracture Fixat | 2016 |
Alendronate for fracture prevention in postmenopause.
Topics: Alendronate; Bone Density Conservation Agents; Female; Fractures, Spontaneous; Humans; Middle Aged; | 2008 |
[New development in bisphosphonate treatment. Fracture prevention by bisphosphonates].
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Therapy, Combination; Evidence-B | 2009 |
[New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates].
Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Drug Admini | 2009 |
[New development in bisphosphonate treatment. When and how long should patients take bisphosphonates for osteoporosis?].
Topics: Alendronate; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Drug Administr | 2009 |
[New development in bisphosphonate treatment. Review of effect on bone metabolism by minodronic acid in primary osteoporosis].
Topics: Alendronate; Amino Acids; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Clinical Tri | 2009 |
Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Sp | 2009 |
[Alendronate for the prevention and treatment of postmenopausal osteoporosis. A survey of a Cochrane review].
Topics: Alendronate; Bone Density Conservation Agents; Evidence-Based Medicine; Female; Fractures, Spontaneo | 2009 |
[Alendronate for treatment of osteoporoses].
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Evidence-Based Medicine; Femoral Fractu | 2009 |
[A-TOP research group/JOINT program].
Topics: Alendronate; Bone Density Conservation Agents; Cholecalciferol; Drug Therapy, Combination; Evidence- | 2009 |
[Biochemical markers of bone turnover. New aspect. Biochemical markers of bone turnover in long term treatment with bisphosphonate].
Topics: Alendronate; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Bone Remodeling; Diphosph | 2009 |
[Effects of SERMs on bone health. Combination therapy with raloxifene].
Topics: Alendronate; Bone Density Conservation Agents; Drug Therapy, Combination; Female; Fractures, Spontan | 2010 |
[Measurement of bone mineral density is necessary for monitoring of bisphosphonate treatment].
Topics: Alendronate; Biomarkers; Bone Density; Diphosphonates; Drug Monitoring; Fractures, Spontaneous; Huma | 2011 |
Canadian consensus on osteoporosis. Preventing osteoporosis among postmenopausal women.
Topics: Aged; Alendronate; Calcium Channel Blockers; Canada; Estrogen Replacement Therapy; Etidronic Acid; F | 2003 |
Bisphosphonates: new indications and methods of administration.
Topics: Alendronate; Animals; Diphosphonates; Etidronic Acid; Fractures, Spontaneous; Humans; Imidazoles; Os | 2003 |
An approach to postmenopausal osteoporosis treatment: a case study review.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Diphosphonates; Estrogen Replacement | 2003 |
The use of bisphosphonates in the treatment of osteoporosis.
Topics: Alendronate; Bone Density; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Male; Osteogenesi | 2005 |
Use of highly potent bisphosphonates in the treatment of osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Remodeling; Diphosp | 2003 |
Oral antiresorptive therapy.
Topics: Administration, Oral; Aged; Alendronate; Diphosphonates; Drug Therapy, Combination; Etidronic Acid; | 2004 |
Fracture prevention in postmenopausal women.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Calcium; Clodronic Acid; Diphosphon | 2006 |
How long should patients take medications for postmenopausal osteoporosis?
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Dr | 2007 |
Is cortical bone hip? What determines cortical bone properties?
Topics: Alendronate; Bone and Bones; Bone Density; Bone Remodeling; Etidronic Acid; Fractures, Spontaneous; | 2007 |
[Glucocorticoid-induced osteoporosis].
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Diphosphonates; Female; Fractu | 2007 |
Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Topics: Alendronate; Bone Density Conservation Agents; Female; Fractures, Bone; Fractures, Spontaneous; Hip | 2008 |
[Alendronate also for women without established osteoporosis?].
Topics: Aged; Alendronate; Bone Density; Diphosphonates; Double-Blind Method; Evidence-Based Medicine; Femal | 2000 |
Osteoporotic fractures at presentation of Cushing's disease: two case reports and a literature review.
Topics: Absorptiometry, Photon; Adult; Alendronate; Bone and Bones; Cushing Syndrome; Fractures, Spontaneous | 2000 |
Background for studies on the treatment of male osteoporosis: state of the art.
Topics: Age Factors; Aged; Aged, 80 and over; Alendronate; Body Height; Body Weight; Bone Density; Fractures | 2000 |
Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs.
Topics: Alendronate; Bone Density; Bone Resorption; Female; Fractures, Spontaneous; Humans; Logistic Models; | 2002 |
7 trials available for alendronate and Fracture, Pathologic
| Article | Year |
|---|---|
Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Fractures, Spontaneous; Hip Joi | 2009 |
Comparison of plain vertebral X-ray and dual-energy X-ray absorptiometry for the identification of older women for fracture prevention in primary care.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Australia; Bone Density; Bone Density | 2013 |
[A head-to-head comparative study for evaluation of effectiveness among drugs for osteoporosis].
Topics: Aged; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Drug Evaluation; | 2006 |
Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Alendronate; Amino Acids; Bone Density; Bone Resorption; Calcium; Drug Ther | 2006 |
[Should bisphosphonate treatment be used for super-old patients with osteoporosis?].
Topics: Age Factors; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; F | 2006 |
An open-label extension study of alendronate treatment in elderly women with osteoporosis.
Topics: Absorptiometry, Photon; Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density; Do | 1999 |
Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Femur Neck; Fractures, Spontaneous; Huma | 1999 |
71 other studies available for alendronate and Fracture, Pathologic
| Article | Year |
|---|---|
A Case Report of Oral Bisphosphonate Treatment for Osteoporosis Leading to Atypical Femoral Fracture and Pathologic Mandibular Fracture.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Femoral Fractures; Fractures, | 2023 |
[Subtrochanteric pathological fracture on bisphosphonates].
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Spontaneous; | 2018 |
Femoral fracture and temporomandibular joint destruction following the use of bisphosphonates.
Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Diphosphonates; Female; Fract | 2015 |
Management after first-line antiresorptive treatment for postmenopausal osteoporosis.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Dose-Respons | 2016 |
Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates.
Topics: Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Con | 2017 |
Maximizing effectiveness of bisphosphonate therapy for osteoporosis.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; | 2008 |
A case report: pregnancy-induced severe osteoporosis with eight vertebral fractures.
Topics: Adult; Alendronate; Back Pain; Bone Density; Bone Density Conservation Agents; Female; Fractures, Sp | 2008 |
Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bo | 2009 |
Pathological fractures in patients caused by bisphosphonate-related osteonecrosis of the jaws: report of 3 cases.
Topics: Administration, Oral; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonat | 2009 |
Do not use bisphosphonate therapy indefinitely for fracture prevention.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Diphosphonates; Female; Fractures, Bone; Fractur | 2008 |
Spontaneous femoral shaft fracture after long-term alendronate.
Topics: Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bony Callus; Female; Femoral Fract | 2009 |
Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Nails; Diphosphonates; | 2009 |
Conservative treatment of a pathologic fracture in a patient with Gorham-Stout disease.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Female; Fracture Fixation; Fractures, Spontaneo | 2010 |
Pathological fracture due to vertebral osteonecrosis associated with pancreatitis.
Topics: Alendronate; Bone and Bones; Bone Density Conservation Agents; Disease Progression; Fat Necrosis; Fr | 2011 |
Unusual case of a conservatively treated pathological fracture after sequestrectomy in a patient with long-term oral bisphosphonate use.
Topics: Administration, Oral; Aged; Alendronate; Anti-Bacterial Agents; Bone Density Conservation Agents; Di | 2011 |
Treatment outcomes in patients with bisphosphonate-related osteonecrosis of the jaws: a prospective study.
Topics: Aged; Alcohol Drinking; Alendronate; Anti-Bacterial Agents; Bone Density Conservation Agents; Chroni | 2010 |
Pathological mandibular fracture after simple molar extraction in a patient with osteogenesis imperfecta treated with alendronate.
Topics: Adult; Alendronate; Diphosphonates; Fractures, Spontaneous; Humans; Male; Mandibular Fractures; Mola | 2010 |
Atraumatic bilateral femur fracture in long-term bisphosphonate use.
Topics: Alendronate; Bone Density Conservation Agents; Female; Femoral Fractures; Fractures, Spontaneous; Hu | 2010 |
Alendronate-associated femoral insufficiency fractures and femoral stress reactions.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Nails; Female; Femoral | 2011 |
The effect of long-term alendronate treatment on cortical thickness of the proximal femur.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Case-Control Studies; Densitometr | 2012 |
Bilateral pathologic hip fractures associated with antiretroviral therapy: a case report.
Topics: Accidental Falls; Adenine; Alendronate; Anti-HIV Agents; Bone Density Conservation Agents; Comorbidi | 2011 |
[Treatment with bisphosphonates as a possible cause of bilateral spontaneous atypical femoral fracture].
Topics: Aged; Alendronate; Bone Density Conservation Agents; Female; Fractures, Spontaneous; Hip Fractures; | 2012 |
[Estimate of the 10-year risk of osteoporotic fractures in the Spanish population].
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Alendronate; Algorithms; Bone Density Conservation | 2013 |
Hemimandibulectomy and vascularized fibula flap in bisphosphonate-induced mandibular osteonecrosis with polycythaemia rubra vera.
Topics: Aged, 80 and over; Alendronate; Aspirin; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone De | 2013 |
Primary hyperparathyroidism with classic and severe skeletal involvement.
Topics: Adenoma; Alendronate; Calcitriol; Calcium Carbonate; Female; Follow-Up Studies; Fractures, Spontaneo | 2010 |
Alendronate treatment for infants with osteogenesis imperfecta: demonstration of efficacy in a mouse model.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Collagen Type I; Diseas | 2002 |
Intravenous pamidronate compared with oral alendronate for the treatment of postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Alendronate; Bone Density; Diphosphonates; Female; Fractures, Spontaneou | 2002 |
Insufficiency fracture of the femoral neck during osteoporosis treatment: a case report.
Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Resorption; Dose-Response Relationship, | 2002 |
[Fragility fracture and its control].
Topics: Accidental Falls; Aged; Alendronate; Female; Fractures, Spontaneous; Hip Fractures; Humans; Male; Os | 2003 |
[Alendronate once a week].
Topics: Alendronate; Bone Density; Female; Fractures, Spontaneous; Gastrointestinal Diseases; Humans; Male; | 2003 |
[Osteoporosis. Don't forget the men!].
Topics: Aged; Alendronate; Bone Density; Clinical Trials as Topic; Fractures, Spontaneous; Humans; Hydroxych | 2003 |
[Cost-effectiveness of alendronate treatment of osteoporosis in Denmark. An economic evaluation based on the Fracture Intervention Trial].
Topics: Aged; Alendronate; Cost of Illness; Cost-Benefit Analysis; Denmark; Drug Costs; Female; Fractures, S | 2003 |
[Effects of different treatments for osteoporosis on prevention of fractures: toward and individualized and economic approach].
Topics: Aged; Aged, 80 and over; Alendronate; Calcitonin; Calcium; Cost-Benefit Analysis; Diphosphonates; Fe | 2004 |
[Bisphosphonates in the prevention of vertebral and non-vertebral fractures in postmenopausal women with osteoporosis].
Topics: Alendronate; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Middle Aged; Os | 2003 |
Putting evidence-based medicine into clinical practice: comparing anti-resorptive agents for the treatment of osteoporosis.
Topics: Alendronate; Bone Resorption; Evidence-Based Medicine; Female; Fractures, Spontaneous; Humans; Meta- | 2004 |
Osteoporosis screening: time to take responsibility.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Calcium Compounds; Female; Follow-Up Studie | 2004 |
Bone mineral density thresholds for pharmacological intervention to prevent fractures.
Topics: Age Distribution; Aged; Aged, 80 and over; Alendronate; Bone Density; Calcium Compounds; Cohort Stud | 2004 |
[Data comparison of osteoporosis patients demonstrates nasal administration is not optimal].
Topics: Administration, Intranasal; Administration, Oral; Aerosols; Aged; Alendronate; Calcitonin; Etidronic | 2004 |
[Risk of osteoporosis in postmenopausal women. When is bone density measurement indicated?].
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Etidronic Acid; Evidence-Based Medicine; Fr | 2004 |
[Are there differences in bisphosphonates? (interview by Dr. Beate Schumacher)].
Topics: Alendronate; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Fractures, Spontaneou | 2004 |
An ongoing six-year innovative osteoporosis disease management program: challenges and success in an IPA physician group environment.
Topics: Absorptiometry, Photon; Age Distribution; Aged; Alendronate; California; Disease Management; Family | 2004 |
[Update 2004. Osteoporosis--management--current status].
Topics: Aged; Aged, 80 and over; Alendronate; Calcium, Dietary; Cross-Sectional Studies; Etidronic Acid; Fem | 2004 |
[Routine osteoporosis therapy].
Topics: Administration, Intranasal; Aged; Alendronate; Calcitonin; Clinical Trials as Topic; Diphosphonates; | 2004 |
[Recent progress in osteoporosis research].
Topics: Aged; Alendronate; Bone Density; Evidence-Based Medicine; Female; Fractures, Spontaneous; Genetic Pr | 2005 |
Teriparatide: new preparation. Osteoporosis: less well evaluated than alendronic acid.
Topics: Alendronate; Animals; Bone Density; Clinical Trials as Topic; Drug Combinations; Female; Fractures, | 2005 |
[Examination and treatment of orthopedic-surgery patients with osteoporosis-related fragility fractures].
Topics: Adult; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Etidronic Acid; F | 2005 |
[Treating with what? Therapy for how long?].
Topics: Adult; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; | 2005 |
[Reliably combined to combat osteoporosis].
Topics: Aged; Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Drug Administration S | 2005 |
[Pregnancy-associated osteoporosis. A new case].
Topics: Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Female; Follow-Up Studies; Fract | 2006 |
Osteoporotic fractures and vitamin D deficiency.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density Conservation Agents; Female; Femoral Fractur | 2006 |
[Drug therapy for prevention of falls and fractures].
Topics: Accidental Falls; Alendronate; Bone Density Conservation Agents; Drug Therapy, Combination; Evidence | 2006 |
[Bisphosphonate-related bilateral mandibular osteochemonecrosis with pathological fracture of the horizontal ramus].
Topics: Aged; Alendronate; Bone Density Conservation Agents; Fractures, Spontaneous; Humans; Male; Mandibula | 2006 |
Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries--an economic evaluation based on the fracture intervention trial.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Computer Simulation; Cost-Be | 2007 |
Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance.
Topics: Aged; Aged, 80 and over; Alendronate; Attitude to Health; Bone Density; Bone Density Conservation Ag | 2007 |
A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis.
Topics: Age Distribution; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Cohort Studies; | 2007 |
[Correlation between studies and general practice].
Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Etidronic Acid; Family Practice; Fe | 2006 |
[Osteoporosis compounds in general practice. That is REAL: in routine practice the better choice].
Topics: Alendronate; Bone Density Conservation Agents; Cohort Studies; Etidronic Acid; Female; Fractures, Sp | 2007 |
[Long term effects of raloxifen on the bones].
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Drug Therapy, Combination; Female; Frac | 2008 |
[Alendronate (Fosamax 10 mg). The first amino-biphosphate for the treatment of women with postmenopausal osteoporosis].
Topics: Aged; Alendronate; Diphosphonates; Dose-Response Relationship, Drug; Female; Femoral Neck Fractures; | 1996 |
[Does alendronate reduce the risk of fractures in postmenopausal women with osteoporosis?].
Topics: Aged; Alendronate; Female; Fractures, Spontaneous; Humans; Middle Aged; Osteoporosis, Postmenopausal | 1997 |
Prevention of hip fractures in older women: a population-based perspective.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Calcium; Estrogen Replacement Therapy; Exercise; | 1998 |
[New knowledge on alendronate (Fosamax) and fractures].
Topics: Alendronate; Diphosphonates; Female; Fractures, Spontaneous; Humans; Osteoporosis, Postmenopausal | 1999 |
[Fast protection against osteoporotic fractures by using alendronat].
Topics: Alendronate; Diphosphonates; Female; Fractures, Spontaneous; Humans; Osteoporosis, Postmenopausal | 1999 |
[Research philosophy and practical research--new knowledge about alendronate and fractures].
Topics: Alendronate; Female; Fractures, Spontaneous; Humans; Osteoporosis, Postmenopausal; Research | 1999 |
[A new type of iliac fracture caused by bone insufficiency].
Topics: Alendronate; Bone Density; Calcium; Densitometry; Diphosphonates; Female; Fractures, Spontaneous; Hu | 1999 |
[Most recent study results show: the bisphosphonate alendronate works more rapidly than previously assumed].
Topics: Alendronate; Evidence-Based Medicine; Fractures, Spontaneous; Hip Fractures; Humans; Osteoporosis; T | 2000 |
Bisphosphonate therapy in fibrous dysplasia.
Topics: Administration, Oral; Adult; Aged; Alendronate; Biomarkers; Bone and Bones; Collagen; Collagen Type | 2001 |
[Osteoporosis and multiple pregnancy--a case report with positive outcome].
Topics: Adult; Alendronate; Bone Density; Calcium Channel Agonists; Calcium, Dietary; Cholecalciferol; Contr | 2001 |
Alendronate for the treatment of osteoporosis in men.
Topics: Alendronate; Bone Density; Climacteric; Female; Fractures, Spontaneous; Humans; Lumbar Vertebrae; Ma | 2001 |
[Economic aspects of osteoporosis therapy. What does a prevented fracture cost?].
Topics: Aged; Alendronate; Cost-Benefit Analysis; Etidronic Acid; Female; Fractures, Spontaneous; Germany; H | 2001 |
[Convenient and well-tolerated therapy of osteoporosis. Preventing fractures only once a week].
Topics: Aged; Alendronate; Drug Administration Schedule; Female; Fractures, Spontaneous; Humans; Middle Aged | 2002 |